A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma

Autor:	G. Lewandowski, M. Rodriguez, M. W. Method, R. H. Ansari, L. Vaccarello
Rok vydání:	2004
Předmět:	Prior treatment Oncology Cancer Research medicine.medical_specialty endocrine system diseases business.industry Phases of clinical research Peritoneal carcinoma Regimen Preliminary report Internal medicine Toxicity medicine Topotecan Platinum sensitive business medicine.drug
Zdroj:	ResearcherID
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2004.22.90140.5063
Popis:	5063 Background: Topotecan 1.5 mg/m2 on days 1 through 5 of a 21-day cycle is an established chemotherapeutic regimen for recurrent ovarian cancer. However, noncumulative myelosuppression has limited topotecan's use in some patients (pts). Topotecan on a weekly schedule has been reported to be active in recurrent ovarian cancer pts with significantly reduced hematologic toxicity. The aim of this trial is to evaluate the safety and antitumor activity of weekly topotecan in pts with platinum-sensitive recurrent ovarian and peritoneal carcinoma. Methods: A prospective multi-institutional study began in July 2002 and is ongoing. Pts were required to have recurrent platinum-sensitive disease and no more than 2 prior treatment regimens. Topotecan was given at a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day cycle and escalated to 5 mg/m2 if well tolerated. Results: To date, 21 pts, 18 with ovarian and 3 with peritoneal carcinoma, have been enrolled. Fifteen are evaluable for toxicity and response. Four have j...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2abfd0024a2d884a6b7f8f0df5d094 https://doi.org/10.1200/jco.2004.22.90140.5063 Zobrazit plný text záznamu